Alzheimer’s Disease: The Imperative of Early Detection and Treatment
With an estimated 7.2 million Americans facing Alzheimer’s, the race for a cure has never been more urgent. Please join Research!America for a congressional briefing that dives into the world of neurodegenerative research and the bold policies needed to conquer it. This event will highlight the status and pace of Alzheimer’s Disease research and delve into the urgent need for innovative partnerships and policies to overcome scientific and clinical challenges.
This briefing is relevant to official duties, widely attended and breakfast will be served.
When: Thursday, March 19, 2026 from 8:30 to 10am; Where: 2045 Rayburn House Office Building – 45 Independence Ave SW, Washington, DC 20515
Moderator: Sue Peschin, President & CEO, Alliance for Aging Research
Panelists:
- Robert Egge, Chief Public Policy Officer, Alzheimer’s Association; President, Alzheimer’s Impact Movement (AIM)
- Melinda Kelley, PhD, Senior Advisor, UsAgainstAlzheimer’s; Former Associate Director, National Institute on Aging, NIH
- Pamela Price, Deputy Director, The Balm In Gilead, Inc
For questions, contact us at [email protected]
Research!America’s “Alzheimer’s Disease: The Imperative of Early Detection and Treatment” briefing was supported in part by Eli Lilly and Company, The Alliance for Aging Research, and The Alzheimer’s Association